{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T23:58:55Z","timestamp":1771891135359,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40273-019-00797-2","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T07:31:23Z","timestamp":1554363083000},"page":"1029-1039","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-4683","authenticated-orcid":false,"given":"Simon","family":"Frey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Stargardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Schrey\u00f6gg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"key":"797_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jcf.2008.03.007","volume":"7","author":"PM Farrell","year":"2008","unstructured":"Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008;7:450\u20133.","journal-title":"J Cyst Fibros."},{"key":"797_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1586\/erp.10.49","volume":"10","author":"EB Hirsch","year":"2010","unstructured":"Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoeconomics Outcomes Res. 2010;10:441\u201351.","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res."},{"key":"797_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1128\/AAC.01041-09","volume":"54","author":"PD Mauldin","year":"2010","unstructured":"Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother. 2010;54:109\u201315.","journal-title":"Antimicrob Agents Chemother."},{"key":"797_CR4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jclinepi.2015.08.026","volume":"70","author":"J Sykes","year":"2016","unstructured":"Sykes J, Stanojevic S, Goss CH, Quon BS, Marshall BC, Petren K, et al. A standardized approach to estimating survival statistics for population-based cystic fibrosis registry cohorts. J Clin Epidemiol. 2016;70:206\u201313.","journal-title":"J Clin Epidemiol."},{"key":"797_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1358\/dot.2013.49.4.1940984","volume":"49","author":"GL McPhail","year":"2013","unstructured":"McPhail GL, Clancy JP. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. Drugs Today (Barc). 2013;49:253\u201360.","journal-title":"Drugs Today (Barc)."},{"key":"797_CR6","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1056\/NEJMra043184","volume":"352","author":"SM Rowe","year":"2005","unstructured":"Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352:1992\u20132001.","journal-title":"N Engl J Med."},{"key":"797_CR7","unstructured":"Zhou M, Balg C, Luhnen M. Ivacaftor (neues Anwendungsgebiet) \u2013 Bewertung gem\u00e4\u00df \u00a7 35a Abs. 1 Satz 10 SGB V. K\u00f6ln: Institute for Quality and Efficiency in Health Care (IQWiG); 2016."},{"key":"797_CR8","unstructured":"Zhou M, Balg C, Luhnen M. Lumacaftor \/ Ivacaftor \u2013 Bewertung gem\u00e4\u00df \u00a7 35a Abs. 1 Satz 10 SGB V. K\u00f6ln: Institute for Quality and Efficiency in Health Care (IQWiG); 2016."},{"key":"797_CR9","unstructured":"Wietrychowski R. Qualit\u00e4tssicherung mukoviszidose. 2012. 2012. \n                    https:\/\/www.muko.info\/fileadmin\/user_upload\/angebote\/qualitaetsmanagement\/register\/berichtsbaende\/qualitaetssicherung_mukoviszidose_2012.pdf\n                    \n                  . Accessed 13 Dec 2018."},{"key":"797_CR10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/01621459.1986.10478354","volume":"81","author":"PW Holland","year":"1986","unstructured":"Holland PW. Statistics and causal inference. J Am Stat Assoc. 1986;81:945\u201360.","journal-title":"J Am Stat Assoc."},{"key":"797_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1023\/A:1020315127304","volume":"2","author":"J Pearl","year":"2001","unstructured":"Pearl J. Causal inference in the health sciences: a conceptual introduction. Health Serv Outcomes Res Methodol. 2001;2:189\u2013220.","journal-title":"Health Serv Outcomes Res Methodol."},{"key":"797_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/01621459.1984.10477060","volume":"79","author":"PR Rosenbaum","year":"1984","unstructured":"Rosenbaum PR. From association to causation in observational studies: the role of tests of strongly ignorable treatment assignment. J Am Stat Assoc. 1984;79:41\u20138.","journal-title":"J Am Stat Assoc."},{"key":"797_CR13","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1037\/h0037350","volume":"66","author":"DB Rubin","year":"1974","unstructured":"Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol. 1974;66:688\u2013701.","journal-title":"J Educ Psychol."},{"key":"797_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1162\/003465304323023651","volume":"86","author":"GW Imbens","year":"2004","unstructured":"Imbens GW. Nonparametric estimation of average treatment effects under exogeneity: a review. Rev Econ Stat. 2004;86:4\u201329.","journal-title":"Rev Econ Stat."},{"key":"797_CR15","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Working paper: cost estimation. 2009. \n                    https:\/\/www.iqwig.de\/download\/Working_Paper_Cost_Estimation.pdf\n                    \n                  . Accessed 13 Dec 2018."},{"key":"797_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/pan\/mpr025","volume":"20","author":"J Hainmueller","year":"2017","unstructured":"Hainmueller J. Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies. Political Anal. 2017;20:25\u201346.","journal-title":"Political Anal."},{"key":"797_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1467-985X.2007.00527.x","volume":"171","author":"K Imai","year":"2008","unstructured":"Imai K, King G, Stuart EA. Misunderstandings between experimentalists and observationalists about causal inference. J R Stat Soc Ser A. 2008;171:481\u2013502.","journal-title":"J R Stat Soc Ser A."},{"key":"797_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8\u201327.","journal-title":"Med Care."},{"key":"797_CR19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1097\/MLR.0b013e31822ebe11","volume":"49","author":"RN Kuo","year":"2011","unstructured":"Kuo RN, Dong YH, Liu JP, Chang CH, Shau WY, Lai MS. Predicting healthcare utilization using a pharmacy-based metric with the WHO\u2019s anatomic therapeutic chemical algorithm. Med Care. 2011;49:1031\u20139.","journal-title":"Med Care."},{"key":"797_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/pan\/mpl013","volume":"15","author":"DE Ho","year":"2007","unstructured":"Ho DE, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Political Anal. 2007;15:199\u2013236.","journal-title":"Political Anal."},{"key":"797_CR21","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/EDE.0b013e3181a819a1","volume":"20","author":"EF Schisterman","year":"2009","unstructured":"Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20:488\u201395.","journal-title":"Epidemiology."},{"key":"797_CR22","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/00001648-199007000-00012","volume":"1","author":"JW Gardner","year":"1990","unstructured":"Gardner JW, Sanborn JS. Years of potential life lost (YPLL)\u2014what does it measure? Epidemiology. 1990;1:322\u20139.","journal-title":"Epidemiology."},{"key":"797_CR23","volume-title":"Kohortensterbetafeln f\u00fcr Deutschland","author":"Federal Statistical Office","year":"2017","unstructured":"Federal Statistical Office. Kohortensterbetafeln f\u00fcr Deutschland. Wiesbaden: Federal Statistical Office; 2017."},{"key":"797_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/pan\/mpj004","volume":"14","author":"G King","year":"2006","unstructured":"King G, Zeng L. The dangers of extreme counterfactuals. Political Anal. 2006;14:131\u201359.","journal-title":"Political Anal."},{"key":"797_CR25","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2165\/00019053-200321140-00002","volume":"21","author":"C Krauth","year":"2003","unstructured":"Krauth C, Jalilvand N, Welte T, Busse R. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics. 2003;21:1001\u201324.","journal-title":"Pharmacoeconomics."},{"key":"797_CR26","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1517\/14656566.9.5.751","volume":"9","author":"JR Weiner","year":"2008","unstructured":"Weiner JR, Toy EL, Sacco P, Duh MS. Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert Opin Pharmacother. 2008;9:751\u201366.","journal-title":"Expert Opin Pharmacother."},{"key":"797_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s40258-015-0211-4","volume":"14","author":"IL Hollin","year":"2016","unstructured":"Hollin IL, Robinson KA. A scoping review of healthcare costs for patients with cystic fibrosis. Appl Health Econ Health Policy. 2016;14:151\u20139.","journal-title":"Appl Health Econ Health Policy."},{"key":"797_CR28","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/ppul.21090","volume":"44","author":"L Ouyang","year":"2009","unstructured":"Ouyang L, Grosse SD, Amendah DD, Schechter MS. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol. 2009;44:989\u201396.","journal-title":"Pediatr Pulmonol."},{"key":"797_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S1569-1993(03)00024-9","volume":"2","author":"U Baumann","year":"2003","unstructured":"Baumann U, Stocklossa C, Greiner W, von der Schulenburg JM, von der Hardt H. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros. 2003;2:84\u201390.","journal-title":"J Cyst Fibros."},{"key":"797_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10198-016-0781-6","volume":"17","author":"K Chevreul","year":"2016","unstructured":"Chevreul K, Michel M, Brigham KB, Lopez-Bastida J, Linertova R, Oliva-Moreno J, et al. Social\/economic costs and health-related quality of life in patients with cystic fibrosis in Europe. Eur J Health Econ. 2016;17:7\u201318.","journal-title":"Eur J Health Econ."},{"key":"797_CR31","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2165\/00019053-200624100-00007","volume":"24","author":"J Schreyogg","year":"2006","unstructured":"Schreyogg J, Hollmeyer H, Bluemel M, Staab D, Busse R. Hospitalisation costs of cystic fibrosis. Pharmacoeconomics. 2006;24:999\u20131009.","journal-title":"Pharmacoeconomics."},{"key":"797_CR32","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2165\/11588870-000000000-00000","volume":"30","author":"M Heimeshoff","year":"2012","unstructured":"Heimeshoff M, Hollmeyer H, Schreyogg J, Tiemann O, Staab D. Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre. Pharmacoeconomics. 2012;30:763\u201377.","journal-title":"Pharmacoeconomics."},{"key":"797_CR33","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.healthpol.2014.12.016","volume":"119","author":"A Angelis","year":"2015","unstructured":"Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119:964\u201379.","journal-title":"Health Policy."},{"key":"797_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.puhe.2017.03.003","volume":"148","author":"D Kopciuch","year":"2017","unstructured":"Kopciuch D, Zaprutko T, Paczkowska A, Nowakowska E. Costs of treatment of adult patients with cystic fibrosis in Poland and internationally. Public Health. 2017;148:49\u201355.","journal-title":"Public Health."},{"key":"797_CR35","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jcf.2014.11.006","volume":"14","author":"K Chevreul","year":"2015","unstructured":"Chevreul K, Brigham KB, Michel M, Rault G. Costs and health-related quality of life of patients with cystic fibrosis and their carers in France. J Cyst Fibros. 2015;14:384\u201391.","journal-title":"J Cyst Fibros."},{"key":"797_CR36","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s40273-017-0530-4","volume":"35","author":"AD Jackson","year":"2017","unstructured":"Jackson AD, Jackson AL, Fletcher G, Doyle G, Harrington M, Zhou S, et al. Estimating direct cost of cystic fibrosis care using Irish registry healthcare resource utilisation data, 2008\u20132012. Pharmacoeconomics. 2017;35:1087\u2013101.","journal-title":"Pharmacoeconomics."},{"key":"797_CR37","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/ppul.24178","volume":"53","author":"SD Grosse","year":"2018","unstructured":"Grosse SD, Do TQN, Vu M, Feng LB, Berry JG, Sawicki GS. Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010\u20132016. Pediatr Pulmonol. 2018;53:1611\u20138.","journal-title":"Pediatr Pulmonol."},{"issue":"46","key":"797_CR38","first-page":"203","volume":"2018","author":"P Vadagam","year":"1995","unstructured":"Vadagam P, Kamal KM. Hospitalization costs of cystic fibrosis in the United States: a retrospective analysis. Hosp Pract. 1995;2018(46):203\u201313.","journal-title":"Hosp Pract"},{"key":"797_CR39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jval.2011.11.027","volume":"15","author":"EM Dewitt","year":"2012","unstructured":"Dewitt EM, Grussemeyer CA, Friedman JY, Dinan MA, Lin L, Schulman KA, et al. Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial. Value Health. 2012;15:277\u201383.","journal-title":"Value Health."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00797-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-019-00797-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00797-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T23:07:18Z","timestamp":1585868838000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-019-00797-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,4]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1007\/s40273-019-00797-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,4]]},"assertion":[{"value":"4 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No funding was received for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"S. Frey, T. Stargardt, U. Schneider and J. Schrey\u00f6gg declare they have no conflict of interest relevant to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"SF and US had complete access to the pseudonymised study dataset and were responsible for data collection. SF, TS, and JS designed the study. SF analysed the data and was responsible for statistical programming. SF and TS prepared the first draft, and JS and US revised the manuscript. All authors approved the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The data that support the findings of this study are owned by the Techniker Krankenkasse (Bramfelder Stra\u00dfe 140, 22305 Hamburg, Germany) and so are not publicly available. To fulfil the legal requirements to access the data, researchers must obtain permission for a specific research question from the German Federal (Social) Insurance Office and conclude a contract with the sickness fund. The study must also be approved by the data protection officer, both at the sickness fund and the research institute, as well as the local ethics committee.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}